Thy Lam
Psychiatric/Mental Health · Vista, CANPI 1083277255
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,267 of the $121,096 with a category attached, or 62.2%. Teva Pharmaceuticals USA, Inc. accounts for 76.6% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $70,382, more than ten times the $998 reported in 2021. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,277 payments — averaging $94.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$93K
- Indivior Inc.$5K
- Alkermes, Inc.$4K
- AbbVie$3K
- Vanda Pharmaceuticals Inc.$3K
- Neurocrine Biosciences, Inc.$3K
- plus $10K from 11 others
What the payments were for
- Consulting fees$1,2381%
- Speaking & faculty fees$75,26762%
- Travel & lodging$14,33012%
- Food & beverage$29,24224%
- Education$1,0191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 335 | $92,811 |
| Indivior Inc. | 91 | $5,159 |
| Alkermes, Inc. | 164 | $3,561 |
| AbbVie | 69 | $3,422 |
| Vanda Pharmaceuticals Inc. | 83 | $3,021 |
| Neurocrine Biosciences, Inc. | 105 | $2,727 |
| Johnson & Johnson | 67 | $2,213 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 126 | $2,154 |
| Otsuka America Pharmaceutical, Inc. | 93 | $2,097 |
| E.r. Squibb & Sons, L.L.C. | 44 | $1,624 |
| Lundbeck LLC | 51 | $716 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $470 |
| Sunovion Pharmaceuticals Inc. | 21 | $466 |
| Axsome Therapeutics, Inc. | 5 | $345 |
| Tempus AI, Inc | 9 | $201 |
| Acadia Pharmaceuticals Inc | 3 | $65 |
| Boehringer Ingelheim | 2 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$50,488
- Austedo XR$34,028
- PERSERIS$3,123
- LYBALVI$2,396
- VRAYLAR$2,124
- AUSTEDO$1,816
- INGREZZA$924
- CAPLYTA$703
- Fanapt$619
- ABILIFY MAINTENA$462
- ARISTADA$460
- ABILIFY ASIMTUFII$352
- REXULTI$337
- COBENFY$121
- ARISTADA INITIO$115
- Auvelity$112
- INVEGA SUSTENNA$101
How this compares
$121,096 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 70 | $803,315 |
| IngrezzaValbenazine Tosylate | 59 | $487,752 |
| Invega SustennaPaliperidone Palmitate | 76 | $221,132 |
| Abilify AsimtufiiAripiprazole | 35 | $174,131 |
| Invega TrinzaPaliperidone Palmitate | 20 | $172,593 |
| PerserisRisperidone | 38 | $112,898 |
| UzedyRisperidone | 27 | $96,469 |
| AristadaAripiprazole Lauroxil | 26 | $81,095 |
| RexultiBrexpiprazole | 32 | $43,260 |
| CaplytaLumateperone Tosylate | 25 | $39,417 |
| LybalviOlanzapine/Samidorphan Malate | 19 | $29,148 |
| VivitrolNaltrexone Microspheres | 18 | $28,805 |
| Lurasidone Hcl | 84 | $13,058 |
| Paliperidone ErPaliperidone | 25 | $4,542 |
| Clozapine | 49 | $3,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $92,811 | $899,78497 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,727 | $487,75259 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $2,213 | $393,72596 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti | $2,097 | $217,39167 claims |
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $3,561 | $139,04863 claims |
| Indivior Inc.Perseris | $5,159 | $112,89838 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,154 | $39,41725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Vista
- Myriame NicolasVista$16K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
- Jonathan LlamasPasadena$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.